- Conditions
- Hypotension
- Interventions
- Sodium chloride, Fentanyl
- Drug
- Lead sponsor
- Loyola University
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Maywood, Illinois
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 289–312
of 2,058
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Anaemia
- Interventions
- GSK1278863 75 mg, GSK1278863 500 mg, Moxifloxacin 400 mg, Placebo matching GSK1278863, Placebo matching Moxifloxacin
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Adenocarcinoma of the Prostate, Stage I Prostate Cancer, Stage II Prostate Cancer, Stage III Prostate Cancer
- Interventions
- placebo, therapeutic conventional surgery, laboratory biomarker analysis, lycopene
- Other · Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Type 2 Diabetes, Obesity
- Interventions
- Tirzepatide, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 414 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 20
- States / cities
- Phoenix, Arizona • Concord, California • Sacramento, California + 17 more
- Conditions
- Diarrhea, Clostridium Difficile Infection
- Interventions
- 0.9% Normal Saline, Clostridium difficile toxoid vaccine, Clostridium difficile toxoid vaccine with adjuvant
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 5
- States / cities
- Tampa, Florida • Marietta, Georgia • Worcester, Massachusetts + 2 more
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- BEA 2180 BR, tiotropium
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years to 84 Years
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 13
- States / cities
- Lakewood, California • Wheat Ridge, Colorado • Pembroke Farms, Florida + 10 more
- Conditions
- Peanut Allergies
- Interventions
- MY006 Low Dose, MY006 Mid Dose, MY006 High Dose, MY006 Selected Dose, Placebo (Vehicle)
- Drug
- Lead sponsor
- Mabylon AG
- Industry
- Eligibility
- 12 Years to 55 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 9
- States / cities
- Little Rock, Arkansas • Aurora, Colorado • Colorado Springs, Colorado + 6 more
- Conditions
- Amyotrophic Lateral Sclerosis, Lou Gehrig's Disease
- Interventions
- coenzyme Q10, Placebo
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 21 Years to 85 Years
- Enrollment
- 185 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 19
- States / cities
- Little Rock, Arkansas • San Francisco, California • Denver, Colorado + 14 more
- Conditions
- Sepsis
- Interventions
- Ascorbic Acid, Normal Saline
- Drug · Other
- Lead sponsor
- Christiana Care Health Services
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Newark, Delaware
- Conditions
- Acute Schizophrenia
- Interventions
- OPC-34712 [Brexpiprazole] High Dose, Experimental: OPC-34712 [Brexpiprazole] Middle Dose, Experimental: OPC-34712 [Brexpiprazole] Low Dose, Placebo
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 636 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 17
- States / cities
- Little Rock, Arkansas • Garden Grove, California • Glendale, California + 12 more
- Conditions
- Cocaine Dependence, Cocaine Addiction
- Interventions
- Metyrapone, Oxazepam, Placebo
- Drug
- Lead sponsor
- Embera NeuroTherapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Shreveport, Louisiana
- Conditions
- Pediculosis
- Interventions
- Group A - Low-Dose Ha44 0.37% w/w, Group B - High Dose Ha44 Gel 0.74% w/w, Group C - Placebo
- Drug
- Lead sponsor
- Dr. Reddy's Laboratories Limited, India
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 142 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 2
- States / cities
- Dinuba, California • Los Angeles, California
- Conditions
- Generalized Myasthenia Gravis
- Interventions
- Placebo, Cladribine Low Dose, Cladribine High Dose
- Other · Drug
- Lead sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 264 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • Longmont, Colorado • Farmington, Connecticut + 20 more
- Conditions
- Bronchiectasis
- Interventions
- BI 1291583, Placebo matching BI 1291583
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 268 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 11
- States / cities
- Newport Beach, California • Sacramento, California • Gainesville, Florida + 8 more
- Conditions
- Staphylococcal Infections
- Interventions
- SA4Ag vaccine low dose, Blood draw, Colonization swab sample, SA4Ag vaccine mid dose, SA4Ag vaccine high dose, SA3Ag vaccine, Blood sample, Placebo, Colonization swab samples
- Biological · Procedure
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 65 Years to 85 Years
- Enrollment
- 284 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2014
- U.S. locations
- 7
- States / cities
- Hollywood, Florida • South Miami, Florida • Overland Park, Kansas + 4 more
- Conditions
- Migraine
- Interventions
- Ubrogepant, Placebo-Matching Ubrogepant
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 1,059 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 125
- States / cities
- Huntsville, Alabama • Saraland, Alabama • Phoenix, Arizona + 102 more
- Conditions
- Type1 Diabetes
- Interventions
- 350mg BID (700mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule, 700mg BID (1400mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule, 1050mg QD (1050mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule, 1050mg BID (2100mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule
- Drug
- Lead sponsor
- Immunomolecular Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 3
- States / cities
- Chula Vista, California • Aurora, Colorado • Renton, Washington
- Conditions
- HIV Infections
- Interventions
- VRC01, Placebo for VRC01
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years · Male only
- Enrollment
- 2,699 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2020
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Francisco, California + 13 more
- Conditions
- Primary IgA Nephropathy
- Interventions
- Sefaxersen (RO7434656), Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 459 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Glendale, California • Los Angeles, California + 15 more
- Conditions
- Alzheimer's Disease
- Interventions
- Posiphen, Placebo
- Drug
- Lead sponsor
- Annovis Bio Inc.
- Industry
- Eligibility
- 55 Years to 89 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 6
- States / cities
- La Jolla, California • Indianapolis, Indiana • Baltimore, Maryland + 3 more
- Conditions
- Healthy
- Interventions
- LX4211 400 mg, LX4211 800 mg, LX4211 Placebo
- Drug
- Lead sponsor
- Lexicon Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2013
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Crohn's Disease
- Interventions
- 4-Aminosalicylic acid, PASER placebo granules
- Drug
- Lead sponsor
- Jacobus Pharmaceutical
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • New York, New York • Charlotte, North Carolina
- Conditions
- Moderate to Severe Chronic Plaque Psoriasis
- Interventions
- AbGn-168H, placebo
- Biological
- Lead sponsor
- AbGenomics B.V Taiwan Branch
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 15
- States / cities
- Little Rock, Arkansas • Rogers, Arkansas • Boynton Beach, Florida + 11 more
- Conditions
- Human Papillomavirus, High-Grade Squamous Intraepithelial Lesions
- Interventions
- TVGV-1, GPI-0100, Placebo
- Biological
- Lead sponsor
- THEVAX Genetics Vaccine
- Industry
- Eligibility
- 18 Years to 55 Years · Female only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 11
- States / cities
- Tucson, Arizona • Lakewood, Colorado • Port Orange, Florida + 8 more